{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:25:44Z","timestamp":1789161944640,"version":"build-2803163510"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"abstract":"ABSTRACT<\/jats:title>\n \n Background:<\/jats:title>\n Due to the high prevalence of depression and anxiety in people with epilepsy, the International League Against Epilepsy Commission on the Neuropsychiatric Aspects of Epilepsy recommends implementing routine screening for depression and anxiety symptoms. Our epilepsy group began administering three screening questionnaires to all clinic patients in 2016: the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), the Beck Anxiety Inventory (BAI) and the Generalized Anxiety Disorder-7 (GAD-7).<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n We aim to review our experience with this screening approach.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n We reviewed 2253 sets of questionnaires completed from January 2018 to March 2020 and studied the actions taken by epileptologists in response to a positive screening.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Thirty-six percent of all assessed patients screened positive on at least one questionnaire: 13.6% screened positive for depression symptoms (NDDI-E \u2265 16), 12.3% for anxiety symptoms (BAI \u2265 22) and 30.3% for GAD symptoms (GAD-7 > 7). Among patients with a positive screening, 36% received a care intervention, 59% did not and 5% declined the neurologist\u2019s recommendation. Among patients for whom an intervention was implemented, 58% were referred to a mental health professional (generally a neuropsychiatrist), 29% had their antiseizure medication adjusted to alleviate their symptoms and 13% received another intervention.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In our clinic, an important proportion of patients screened positive for depression and\/or anxiety symptoms. Fewer than half received a management option to alleviate their symptoms. We conclude that while routine screening increases the detection of depression and anxiety among epilepsy patients, it must be accompanied by effective interventions and access to mental-health professionals.<\/jats:p>\n <\/jats:sec>","DOI":"10.1017\/cjn.2025.10491","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:15:12Z","timestamp":1765354512000},"page":"1-9","source":"Crossref","is-referenced-by-count":7,"title":["Screening and Management of Depression and Anxiety in People With Epilepsy: A Quality Improvement Study"],"prefix":"10.1017","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6010-6527","authenticated-orcid":false,"given":"Imane","family":"Injar","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0410a8y51","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre de Recherche du CHUM (CRCHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-7347","authenticated-orcid":false,"given":"Mark","family":"Keezer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0410a8y51","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre de Recherche du CHUM (CRCHUM)"},{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Lapalme-Remis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0410a8y51","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre de Recherche du CHUM (CRCHUM)"},{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laury","family":"Chamelian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0410a8y51","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre de Recherche du CHUM (CRCHUM)"},{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Bou Assi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0410a8y51","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre de Recherche du CHUM (CRCHUM)"},{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang Khoa","family":"Nguyen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0410a8y51","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre de Recherche du CHUM (CRCHUM)"},{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,12,10]]},"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167125104915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:01:20Z","timestamp":1767686480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167125104915\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":0,"alternative-id":["S0317167125104915"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2025.10491","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}